Estuary Biotherapeutics Emerges from Stealth with $93 Million for Kidney Gene Therapy
Estuary Biotherapeutics has emerged from stealth with a $93 million Series A round led by RA Capital, bringing its total announced funding to $103 million to treat a genetic kidney disease.
Estuary Biotherapeutics has emerged from stealth with a $93 million Series A financing round led by RA Capital Management, bringing its total reported funding to $103 million, including a previous $10 million seed round, according to BioPharma Dive.
Headquartered in Menlo Park, California, the company is developing AAV vector-mediated gene therapies for autosomal dominant polycystic kidney disease, a genetic disorder.
The company expects its treatment "EST-201" to enter human testing in 2027, followed by "EST-101" in 2028.
Deep Track Capital, Biogen New Ventures, UPMC Enterprises, 4BIO Capital, and GV also participated in the round.
What do these terms mean?
Gene therapy: A treatment that works by repairing or replacing a disease-causing gene rather than just treating symptoms.
AAV vectors: Modified viruses used to safely deliver the healthy gene to target cells with relative safety.
Series A: The first major funding round for a company after the seed round, typically funding product development and testing.
Human testing: The phase where trials move from the laboratory and animals to patients to measure safety and efficacy.
Weekly Newsletter
Read between the lines before everyone else. Decode the most important economic, tech, and decision-maker movements in the region.. in 5 minutes every Saturday.
